(Update1) Patent owners see duplicative IPRs as example of an unfair U.S. patent system

A growing number of patent owners believe that the high percentage of duplicative filings of inter partes reviews (IPR) by large companies including Apple, Microsoft, Google, Samsung and LG Electronics reveals how imbalanced the patent system is in the U.S. and that significant changes such as a limit of one IPR per patent are necessary [...]

By | September 20th, 2018|IPRs, Patent Investing, PTAB, Supreme Court, USPTO|0 Comments

TiVo may have a bigger licensing opportunity against Amazon than Comcast, analyst says

TiVo Corp. (TIVO), the patent licensing company locked in a multi-hundred million patent infringement dispute with Comcast Corp., may have an even bigger potential licensing opportunity in Amazon’s development of a device that would record and store live TV and allow consumers to stream shows to their mobile devices. That’s the assessment of Eric Wold, [...]

By | August 23rd, 2018|IPRs, litigation, Patent Investing|0 Comments

Federal Circuit affirms PTAB decision that tribal sovereign immunity doesn’t apply to IPRs

The Court of Appeals for the Federal Circuit as expected affirmed the Patent Trial and Appeal Board’s decision rejecting the St. Regis Mohawk Tribe’s attempt to use it tribal sovereign immunity to shield patents owned by Allergan PLC from challenge in an inter partes review. In 2017, the St. Regis Mohawk Tribe and Allergan announced [...]

By | July 20th, 2018|Federal Circuit, IPRs, Patent Investing|0 Comments

(Update1) Senator Hatch proposes amendment to Hatch-Waxman to prevent gaming of drug patent system with IPRs

Senator Orrin Hatch (R-UT), the chairman of the Senate Republican High-Tech Task Force and co-author of the Hatch-Waxman Act, filed an amendment in the Senate Judiciary Committee to restore the careful balance the Hatch-Waxman Act struck to incentivize generic drug development. The amendment, dubbed the Hatch-Waxman Integrity Act of 2018, would prevent generic drug companies [...]

By | June 13th, 2018|drug patents, IPRs, Patent Investing|0 Comments